Interesting research - thank you @jellyroll for bringing it up from discussion.
On examination of the patents submitted by Invex to the US and EU patent offices, there was no mention of treating cataracts as an innovative step worthy of intellectual property protection.
From my reading, for individuals that have diabetes, they are twice as likely to develop Cataracts. My suspicion is that the glucose lowering effect of a GLP-1 improves glycemic control which reduces the Cataract risk, rather than it's intracranial lowering effect.
I still remain excited about the additional indications that a GLP-1 that lowers intracranial pressure can achieve, such as Traumatic Brain Injury, Stroke and Hydrocephalus.
Add to My Watchlist
What is My Watchlist?
